| Literature DB >> 31881674 |
Feng-Sheng Wang1, Wu-Hsiung Wu1, Wei-Shiang Hsiu1, Yan-Jun Liu1, Kuan-Wei Chuang1.
Abstract
Although cancer has historically been regarded as a cell proliferation disorder, it has recently been considered a metabolic disease. The first discovery of metabolic alterations in cancer cells refers to Otto Warburg's observations. Cancer metabolism results in alterations in metabolic fluxes that are evident in cancer cells compared with most normal tissue cells. This study applied protein expressions of normal and cancer cells to reconstruct two tissue-specific genome-scale metabolic models. Both models were employed in a tri-level optimization framework to infer oncogenes. Moreover, this study also introduced enzyme pseudo-coding numbers in the gene association expression to avoid performing posterior decision-making that is necessary for the reaction-based method. Colorectal cancer (CRC) was the topic of this case study, and 20 top-ranked oncogenes were determined. Notably, these dysregulated genes were involved in various metabolic subsystems and compartments. We found that the average similarity ratio for each dysregulation is higher than 98%, and the extent of similarity for flux changes is higher than 93%. On the basis of surveys of PubMed and GeneCards, these oncogenes were also investigated in various carcinomas and diseases. Most dysregulated genes connect to catalase that acts as a hub and connects protein signaling pathways, such as those involving TP53, mTOR, AKT1, MAPK1, EGFR, MYC, CDK8, and RAS family.Entities:
Keywords: cancer cell metabolism; constraint-based modeling; flux balance analysis; multi-level optimization; oncogene; tissue-specific metabolic models
Year: 2019 PMID: 31881674 PMCID: PMC7022839 DOI: 10.3390/metabo10010016
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Figure 1Roadmap of reconstruction of genome-scale metabolic networks for normal and cancer tissues. (A) Protein expressions of normal and cancerous colorectal tissues are accessed from HPA, and gene encoding enzymes are obtained through the gene association of Recon 2.2. (B) The acquired data are used to determine high, medium, and negative confidence sets of reactions. (C) The metabolic networks of cancer and healthy cells for the colorectal tissue are reconstructed using the CORDA algorithm. (D) Metabolic networks are stored in XML format. (E) The SBP tool is used to transfer metabolic networks to their stoichiometric models and gene-protein-reaction models. (F) Both cancer and healthy models are merged into a basal model. (G) The basal model can be used for further analysis and simulation.
Figure 2Flowchart of the in silico experiment for inferring oncogenes. (A) Reconstruct the cancer and normal models. (B) Compute the flux distributions of cancer and normal models. (C) Build the flux template according to the flux distributions of cancer and normal models. (D)–(I) Simulation of a wet lab experiment for determining oncogenes. Orange arrows indicate the building processes of the flux template that acted as the control in the oncogene inference problem. Red arrows present the mutant schemes for formulating the tri-level oncogene inference problem.
Figure 3Example for building a gene-protein-reaction model using the enzyme pseudo-coding numbers. (A) Three reactions and their gene associations. (B) Reduced gene associations and encoded genes of the enzyme. E2 is a redundant enzyme that is identical to E1 and catalyzed the same reactions. r2 is catalyzed by the isozymes (E1 and E3). E1 is encoded by G1, and E3 is encoded by a complex of G3 and G4.
Figure 4Statistics of cancer (CA) and healthy (HT) metabolomic models. Numbers of genes, species, and reactions for CA and HT models reconstruted by the CORDA algorithm taking the Recon 2.2 general model and HPA protein expression data as input. The basal (BL) model is composed of the union set of HT and CA models.
Top 20 one-hit oncogenes.
| Gene | Pathway | Ave. CR | Ave. SR | Disease (Score) | Remark | |
|---|---|---|---|---|---|---|
|
| Ethanol degradation | 0.934 | 0.982 | 1.46 | Gonadoblastoma (1.42) | Related to ROS signaling pathway [ |
|
| Pentose phosphate pathway | 0.931 | 0.981 | 6.57 | Fibrosarcoma (1.08) | Gastric cancer [ |
|
| TRNA aminoacylation | 0.935 | 0.982 | 0.4926 | Sudden Cardiac Failure, Infantile (2.83) | Colorectal cancer [ |
|
| Ketone body metabolism | 0.935 | 0.982 | 3.8 | 3-Hydroxy-3-Methylglutaryl-Coa Lyase Deficiency (2.83) | Nasopharyngeal carcinoma [ |
|
| Alanine and aspartate metabolism | 0.933 | 0.982 | 0.0133 | Hyperoxaluria, Primary, Type I (2.83) | Colorectal cancer [ |
|
| PAK pathway | 0.932 | 0.982 | 4.35 | NA | Oral squamous cell carcinoma [ |
|
| Glyoxylate metabolism and glycine degradation | 0.934 | 0.982 | 0.0018 | Hyperoxaluria, Primary, Type Ii (2.83) | Hyperoxaluria [ |
|
| Methylene blue pathway | 0.827 | 0.980 | 1.37 | Anemia (2.63) | Colorectal cancer [ |
|
| Pentose phosphate pathway | 0.918 | 0.982 | 0.0018 | Cortisone Reductase Deficiency 1 (2.83) | Cancer cell lines for colon, breast and lung [ |
|
| Carbohydrate digestion and absorption | 0.936 | 0.982 | 4.55 | Albinism, Oculocutaneous, Type Iv (1.26) | Breast cancer [ |
|
| Mineral absorption | 0.934 | 0.982 | 0.8577 | Inflammatory Diarrhea (1.50) | Colorectal cancer cell lines [ |
|
| Carbohydrate digestion and absorption | 0.930 | 0.982 | 0.4026 | Glycogen Storage Disease (2.83) | Congenital hyperinsulinism of infancy [ |
|
| Osteoclast signaling | 0.932 | 0.982 | 1.9 | Lichtenstein-Knorr Syndrome (2.83) | Colon cancer cells [ |
|
| Peroxisomal lipid metabolism | 0.933 | 0.982 | 1.84 | Malonyl-Coa Decarboxylase Deficiency (2.83) Pain-Chronic (1.43) | Proliferation of cancer cell lines [ |
|
| Urea cycle and metabolism of amino groups | 0.934 | 0.982 | 3.44 | Lung Cancer Susceptibility (0.42) | Related to metastasis of cancer cells [ |
|
| Arginine and proline metabolism | 0.933 | 0.981 | 4.2 | Primary Hyperoxaluria (1.34) | Hepatocellular carcinoma [ |
|
| Nucleotide metabolism | 0.934 | 0.982 | 8.81 | Leber Congenital Amaurosis (2.83) | Small cell lung cancer [ |
|
| Mineral absorption | 0.934 | 0.981 | 0.0013 | Iron Metabolism Disease (1.36) | Breast and prostate cancer cells [ |
|
| Taurine and hypotaurine metabolism | 0.934 | 0.982 | 1.08 | Small Intestine Cancer (1.31) | Colorectal cancer [ |
|
| Triacylglycerol degradation | 0.940 | 0.981 | 0.0319 | Hepatic Lipase Deficiency (2.83) | Colorectal cancer [ |
Average similarity for flux change ratio; Average similarity ratio of the mutant flux pattern to the templat; Disease is obtained from GeneCards database and score is accessed from GeneCards; Brief description of gene function and references from PubMed and cancer databases.
Figure 5Protein-protein interactions (PPIs). (A) PPIs of the inferred oncogene CAT. CAT is strongly connected with the TP53, mTOR, AKT1, MAPK1, EGFR, MYC, CDK8, and RAS family. (B) CAT acts as a hub with most dysregulated genes linked to it.
Top six one-hit reactions. The criteria may overestimate or underestimate compared with the results solved by the pseudo-enzyme strategy.
| Reaction | Gene | Other Regulated Reactions | Isozyme | Ave. CR | Ave. SR | Remark |
|---|---|---|---|---|---|---|
| GPI |
| – | – | 0.931 | 0.981 | Gastric cancer [ |
| r0161 |
| – | – | 0.933 | 0.982 | Colorectal cancer [ |
| r0249 |
| RPI | – | 0.935 | 0.981 | Overestimated. |
| HMGLx |
| HMGLx | HMGCLL1 | 0.934 | 0.982 | Nasopharyngeal carcinoma [ |
| r0616 |
| PROD2, r0615, PRO1x | – | 0.934 | 0.982 | Hepatocellular carcinoma [ |
| CATp |
| CATPm, r0010 | – | 0.932 | 0.982 | Related to ROS signaling [ |
| CATm |
| CATp, r0010 | – | 0.838 | 0.979 | Underestimated, ROS signaling [ |
| r0010 |
| CATm, CATp | – | 0.867 | 0.981 | Underestimated, ROS signaling [ |
Average similarity for flux change ratio; Average similarity ratio of the mutant flux pattern to the template; Brief description of gene function and references from PubMed and cancer databases.
Figure 6The number of metabolites in different categories for the template and 20 mutants. The definition of categories is presented in Supplementary Materials (Figure S4).
Figure 7Flux variance patterns for the template and 20 mutants. Green indicates complete decrease, dark green means partial or inclusive decrease, and red denotes complete increase.